<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01023269</url>
  </required_header>
  <id_info>
    <org_study_id>1.02.7004</org_study_id>
    <nct_id>NCT01023269</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Pudendal Neuromodulation for the Treatment of Neurogenic Overactive Bladder</brief_title>
  <acronym>ACCEPTANCE</acronym>
  <official_title>Phase IV, Multi-center, Randomized, Cross-over Study to Demonstrate the Efficacy of Pudendal Neuromodulation for the Treatment of Neurogenic Overactive Bladder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic International Trading Sarl</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic International Trading Sarl</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to demonstrate that treatment with low level stimulation of the bladder
      muscles reduces symptoms of urinary incontinence in comparison with no stimulation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Medtronic InterStim device delivers stimulation therapy for the treatment of chronic
      intractable (functional) disorders of the pelvis and lower urinary or intestinal tract
      through the sacral nerve or the pudendal nerve systems.

      This trial is designed to demonstrate that neuromodulation of the pudendal nerve will
      effectively treat patients with neurogenic overactive bladder. Symptoms of urinary
      incontinence are compared when stimulation is switched on for 4 weeks to stimulation switched
      off for 4 weeks. After the eight week crossover period, all patients receive treatment and
      are followed up within the study for 12 months post implant.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    difficulty in the enrolment
  </why_stopped>
  <start_date>December 2009</start_date>
  <completion_date type="Anticipated">September 2012</completion_date>
  <primary_completion_date type="Anticipated">August 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The mean difference in functional bladder capacity, as measured by the the average voiding volume per episode, between stimulation ON for 4 weeks and OFF for 4 weeks.</measure>
    <time_frame>8 weeks after neurostimulator implant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urge Urinary Incontinence, as measured using the number of leaks or notice of leaks, will be compared between stimulation ON for 4 weeks and stimulation off for 4 weeks.</measure>
    <time_frame>8 weeks from neurostimulator implant</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Neurogenic Overactive Bladder</condition>
  <condition>Urinary Incontinence</condition>
  <condition>Detrusor Overactivity</condition>
  <arm_group>
    <arm_group_label>ON / OFF</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Stimulation ON for 4 weeks, followed by stimulation OFF for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OFF / ON</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Stimulation OFF for 4 weeks, followed by stimulation ON for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>InterStim Therapy</intervention_name>
    <description>Neuromodulation therapy which delivers low level electrical stimulation to bladder wall for the treatment of overactive bladder with urinary incontinence.</description>
    <arm_group_label>ON / OFF</arm_group_label>
    <arm_group_label>OFF / ON</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Incomplete upper motor neuron lesion

          -  Detrusor overactivity

          -  Two leaks or two notices of leaks per day

          -  Mean functional bladder capacity (volume voided per episode) of ≥100 ml

        Exclusion Criteria:

          -  Complete spinal lesion or complete bilateral lesion of sacral / pudendal nerves.

          -  Degenerative disease of the central nervous system
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michele Spinelli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale Niguarda Ca' Granda, Milan, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karel Everaert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Ghent</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philip Van Kerrebroeck, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Ziekenhuis, Maastricht, The Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emmanuel Chartier-Kastler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital de la Pitié Salpétrière, Paris, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arndt Van Ophoven, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Marienhospital Herne Klinikum der Ruhr-Universität, Herne, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karl Sievert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik für Urologie Oberarzt-Sekretariat, Tübingen, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Suzy Elneil, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Hospital for Neurology and Neurosurgery, London, UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Lyon-Sud</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Pitié Salpétrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marienhospital Herne, Klinikum der Ruhr-Universitaet Bochum</name>
      <address>
        <city>Herne</city>
        <zip>44627</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Urologie Oberarzt-Sekretaria</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niguarda Ospedale Ca' Granda</name>
      <address>
        <city>Milan</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital for Neurology and Neurosurgery</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2009</study_first_submitted>
  <study_first_submitted_qc>December 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2009</study_first_posted>
  <last_update_submitted>January 13, 2012</last_update_submitted>
  <last_update_submitted_qc>January 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neurogenic overactive bladder</keyword>
  <keyword>Urinary incontinence due to incomplete spinal cord injury</keyword>
  <keyword>Neuromodulation</keyword>
  <keyword>Neuromodulation for treatment of neurogenic overactive bladder</keyword>
  <keyword>Patients with Urge urinary incontinence and detrusor overactivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>May 18, 2016</submitted>
    <returned>June 27, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

